Comparative Pharmacology
Head-to-head clinical analysis: HYDRO D versus METHYCLOTHIAZIDE AND DESERPIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO D versus METHYCLOTHIAZIDE AND DESERPIDINE.
HYDRO-D vs METHYCLOTHIAZIDE AND DESERPIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, reducing sodium and water reabsorption and increasing potassium excretion.
Methyclothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume; deserpidine is a Rauwolfia alkaloid that depletes catecholamines from peripheral sympathetic nerve endings, lowering peripheral vascular resistance.
25-100 mg orally once daily in the morning.
One tablet (5 mg methyclothiazide / 0.25 mg deserpidine) orally once daily. Maximum dose: one tablet daily.
None Documented
None Documented
Terminal elimination half-life: 5.6 to 15 hours; prolonged in renal impairment and in patients with heart failure.
Methyclothiazide: terminal half-life 17-24 hours, permitting once-daily dosing. Deserpidine: 50-100 hours, allowing accumulation with repeated dosing.
Renal: approximately 50% as unchanged drug; biliary/fecal: approximately 50% as metabolites and minor unchanged drug.
Methyclothiazide: primarily renal excretion (60-70% unchanged) via tubular secretion; Deserpidine: extensive hepatic metabolism, <1% excreted unchanged in urine, with metabolites excreted in urine (40%) and feces (60%).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic and Antihypertensive